Proteasomal adaptations underlying carfilzomib‐resistance in human bone marrow plasma cells-Reference-Cited by-同舟云学术

Proteasomal adaptations underlying carfilzomib‐resistance in human bone marrow plasma cells

Published:2019-12-11 Issue:2 Volume:20 Page:399-410
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Woodle E. Steve¹^ORCID,Tremblay Simon¹²^ORCID,Brailey Paul³,Girnita Alin¹³,Alloway Rita R.¹⁴,Aronow Bruce⁵,Dasgupta Nupur⁵,Ebstein Frederic⁶,Kloetzel Peter‐Michael⁶,Lee Min Jae⁷,Kim Kyung B.⁷,Singh Harinder⁸,Driscoll James J.⁹¹⁰^ORCID

Affiliation:

1. Division of Transplantation Department of Surgery Cincinnati Ohio

2. Department of Environmental Health Division of EpidemiologyCincinnati Ohio

3. Hoxworth Blood Center Transplant Immunology DivisionCincinnati Ohio

4. Division of Nephrology Department of MedicineCincinnati Ohio

5. Department of Biomedical Informatics Cincinnati Children’s Hospital Medical Center Cincinnati Ohio

6. Institute for Biochemistry Charité – University Medicine Berlin Berlin Germany

7. Department of Pharmaceutical Sciences College of PharmacyUniversity of Kentucky Lexington Kentucky

8. Division of Immunobiology Cincinnati Children’s Hospital Medical Center Cincinnati Ohio

9. Department of Internal Medicine Division of Hematology and OncologyCincinnati Ohio

10. University of Cincinnati Cancer Institute Cincinnati Ohio

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.15634

Reference49 articles.

1. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

2. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

3. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

4. Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

5. Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) Conference

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma;2024-05-31

2. Identification of <i>TNFRSF1A</i> as a novel regulator of carfilzomib resistance in multiple myeloma;Oncology Research;2024

3. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells;The Journal of Immunology;2023-11-15

4. Effects of in vivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates;American Journal of Transplantation;2023-06

5. Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant;Science Advances;2023-05-19